Loading...
In September 2026, the U.S. FDA approved the use of finerenone (Kerendia) in adults with chronic kidney disease associated with type 1 diabetes. The specific indication is to “reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease.” This nonsteroidal aldosterone receptor antagonist was previously approved to slow progression of renal disease only in patients with type 2 diabetes.
The new approval was based on an industry-sponsored randomized trial involving 242 patients with type 1 diabetes, an estimated glomerular filtration rate (eGFR) between 25 and 90 ml/minute/1.73 m2 (mean, 59), and a urinary albumin-to-creatinine ra…